Clinical Trials
21 trialsNCT07320950 2026-01-06
Neuroprotective Effect of Neurotropin on Chronic OXA-induced Neurotoxicity in Stage II and Stage III CRC Patients
Sun Yat-sen University
Phase 3 Completed
NCT01099449 2022-11-03
Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity in Patients With Colon Cancer or Rectal Cancer Receiving Oxaliplatin-Based Combination Chemotherapy
Alliance for Clinical Trials in Oncology
Phase 3 Completed
NCT01372774 2022-09-16
Stereotactic Radiosurgery or Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases That Have Been Removed By Surgery
Alliance for Clinical Trials in Oncology
Phase 3 Completed
NCT00039780 2022-07-13
Evaluation of BNP7787 for the Prevention of Neurotoxicity in Metastatic Breast Cancer Patients Receiving Weekly Paclitaxel
BioNumerik Pharmaceuticals, Inc.
Phase 3 Completed
NCT00369564 2021-08-11
Glutamic Acid in Reducing Nerve Damage Caused by Vincristine in Young Patients With Cancer
University of South Florida
Phase 3 Completed
NCT00068445 2018-05-04
Lamotrigine in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer
Alliance for Clinical Trials in Oncology
Phase 3 Completed
NCT02486198 2018-02-05
Monosialotetrahexosylganglioside for Treatment of Oxaliplatin Induced Neurotoxicity in Gastrointestinal Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 3 Completed
NCT00516503 2017-08-24
Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer
Alliance for Clinical Trials in Oncology
Phase 3 Completed
NCT00566852 2017-08-21
Memantine in Preventing Side Effects in Patients Undergoing Whole-Brain Radiation Therapy for Brain Metastases From Solid Tumors
Radiation Therapy Oncology Group
Phase 3 Completed
NCT00775645 2017-08-14
S0715: Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, II, or IIIA Breast Cancer Undergoing Chemo
SWOG Cancer Research Network
Phase 3 Completed
NCT00489411 2017-04-26
Duloxetine in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer
Alliance for Clinical Trials in Oncology
Phase 3 Completed
NCT02311907 2017-02-23
Glutathione in Preventing Peripheral Neuropathy Caused by Paclitaxel and Carboplatin in Patients With Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer
Alliance for Clinical Trials in Oncology
Phase 3 Completed
NCT00316914 2016-08-11
Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity Caused By Oxaliplatin in Patients Receiving Combination Chemotherapy for Stage II, Stage III, or Stage IV Colorectal Cancer That Has Been Completely Removed By Surgery
Alliance for Clinical Trials in Oncology
Phase 3 Completed
NCT00046891 2016-07-06
EGb761 in Maintaining Mental Clarity in Women Receiving Chemotherapy for Newly Diagnosed Breast Cancer
Alliance for Clinical Trials in Oncology
Phase 3 Completed
NCT00363129 2016-07-06
Vitamin E in Preventing Peripheral Neuropathy Caused by Chemotherapy in Patients Receiving Chemotherapy for Cancer
Alliance for Clinical Trials in Oncology
Phase 3 Completed
NCT00027963 2016-07-04
Gabapentin in Treating Peripheral Neuropathy in Cancer Patients Undergoing Chemotherapy
Alliance for Clinical Trials in Oncology
Phase 3 Completed
NCT00305188 2016-05-04
Evaluation of the Efficacy of Xaliproden (SR57746A) in Preventing the Neurotoxicity of Oxaliplatin / 5FU/LV Chemotherapy.
Sanofi
Phase 3 Completed
NCT00471445 2015-11-09
Topical Amitriptyline and Ketamine Cream in Treating Peripheral Neuropathy Caused by Chemotherapy in Cancer Patients
University of Rochester
Phase 3 Completed
NCT00112996 2014-04-08
Alpha-Lipoic Acid in Preventing Peripheral Neuropathy in Patients Receiving Chemotherapy for Cancer
M.D. Anderson Cancer Center
Phase 3 Completed
NCT00058071 2013-07-09
Amifostine in Treating Peripheral Neuropathy in Patients Who Have Received Chemotherapy for Cancer
GOG Foundation
Phase 3 Completed
NCT00272051 2006-09-13
XENOX - Evaluation of the Efficacy of Xaliproden in Reducing the Neurotoxicity of the Oxaliplatin + 5-FU/LV Chemotherapy
Sanofi
Phase 3 Completed